99mTc-CNDG Injection in the Diagnosis of Malignant Tumors

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Sep 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called 99mTc-CN7DG, which is designed to help doctors see malignant tumors (cancerous growths) more clearly using a type of scanning called SPECT. Currently, the most common imaging agent used is 18F-FDG, but it can be expensive and harder to produce. This new agent aims to provide a simpler, more cost-effective option that could improve the way tumors are diagnosed and monitored.

To participate in this study, you need to be between 18 and 70 years old and have been diagnosed with certain types of cancer, such as glioma, colorectal, pancreatic, lung, or breast cancer. You should also have a solid tumor that is larger than 2 cm and be scheduled for surgery or a biopsy. If you decide to join, you'll undergo imaging with this new agent, which will help researchers see how well it works compared to existing methods. It's important to note that if you have already had treatments like chemotherapy or if you're pregnant or breastfeeding, you won't be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-70 years old
• • Patients diagnosed with malignant glioma, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, or other malignant tumors through imaging techniques such as MRI, CT, and ultrasound, and who are scheduled for surgical resection or biopsy
• • Solid tumor sizes greater than 2cm
• • Voluntarily agree to participate and sign an informed consent form
• • Can provide complete surgical records, pathological results, control data, and clinical follow-up results
• Exclusion Criteria:
• • Pre-treatment such as chemotherapy and targeted therapy has been administered
• • Pregnancy and breastfeeding
• • Claustrophobia
• • The condition is severe and difficult to cooperate with
• • Unable to obtain relevant control imaging data and clinical information